Paramedical tattoos lead Healio’s 2024 vitiligo coverage
Key takeaways:
- An article on the use of paramedical tattoos as treatment was the most-read vitiligo article in 2024.
- Videos with Joel M. Gelfand, MD, MSCE, and John E. Harris, MD, PhD, also made the list.
Paramedical tattoos can be used for vitiligo by color matching tattoo ink with patients’ skin tones in vitiligo-affected areas, according to a presenter at the American Society for Dermatologic Surgery Annual Meeting.
Tattoo artists can create skin-colored ink by combining inorganic pigments, which are made of mineral oxides that comprise fade-resistant black and white inks, with organic pigments which are made of azo and polycyclic compounds that create more vibrant colors. A recap of the presentation was Healio’s top vitiligo story of 2024.
Other top stories include Healio’s Beneath the Surface video series, clinical data on novel treatment options and more:
‘Just like... Monet’: How paramedical tattoos can be used to treat vitiligo
Tattoos are not just for decorative purposes; they can also be used to treat vitiligo, a presenter said. Read more.
Beneath the Surface: Vitiligo treatment landscape expanding
Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.
In this edition, Gelfand, continues an in-depth discussion about vitiligo with John E. Harris, MD, PhD, about vitiligo treatment options, timelines and success rates, as well as how to prepare patients to set their expectations accordingly. Watch video.
Beneath the Surface: The science behind vitiligo
In the first part of a three-part collection, Gelf and Harris discuss the history of vitiligo, its triggers and the science behind the disease. Watch video.
Upadacitinib improves vitiligo among patients without reaching plateau for 1 year
In this phase 2 study, researchers evaluated the efficacy and safety of once-daily upadacitinib for the treatment of nonsegmental vitiligo for 52 weeks. Read more.
Safety data show ruxolitinib cream well tolerated in atopic dermatitis, vitiligo at 1 year
Safety data for ruxolitinib cream (Opzelura, Incyte), a Janus kinase inhibitor, in the first year after its approval has shown that the drug is generally well tolerated for the treatment of atopic dermatitis or vitiligo, according to a postmarketing review. Read more.
Beneath the Surface: Approaching vitiligo in clinic
In this edition of Beneath the Surface, Gelfand and Harris discuss how best to address the concerns of patients with vitiligo, how the disease affects the immune system and how vitiligo’s variants affect treatment options. Watch video.
New data show ritlecitinib plus phototherapy beneficial for nonsegmental vitiligo
In patients with active nonsegmental vitiligo, ritlecitinib (Litfulo, Pfizer) monotherapy or paired with twice weekly narrowband ultraviolet B phototherapy improved facial and total body repigmentation, according to a speaker at the American Academy of Dermatology meeting. Read more.
Autologous skin cell suspension transplant efficacious in vitiligo
With a 1:20 donor-to-recipient ratio, the RECELL autologous cell harvesting device (Avita Medical) prepares non-cultured autologous skin cell suspension at the point-of-care, according to the study. Read more.
Investigators, patients satisfied with RECELL for treatment of vitiligo
In a multicenter, 52-week study, researchers evaluated the efficacy and safety of RECELL, an autologous cell harvesting device, for the treatment of vitiligo in all skin types. Read more.
First patient dosed in phase 2b trial of VYN201 for treatment of nonsegmental vitiligo
VYN201 is a pan-bromodomain BET inhibitor designed to be locally administered to address inflammatory cell signaling pathways. Following positive results from VYNE Therapeutics’ phase 1b trial of VYN201, the company has now begun its phase 2b trial. Read more.